Inventiva’s lanifibranor has been tipped to become a blockbuster in the fatty liver disease non-alcoholic steatohepatitis (NASH) after it became the first drug to hit two regulatory goals in a trial.
Intercept Pharmaceuticals has accused the FDA of moving the goalposts during its review of a potential blockbuster drug for the fatty liver disease known as NASH following a rejection. Intercept’s CEO ...
A dealership's rating is based on all of their reviews, with more weight given to recent reviews. Includes reviews of Chuck Nash Chevrolet, Buick, GMC from DealerRater. Want to share your experience ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback